Abdi İbrahim Expands Biotechnology Portfolio

Abdi İbrahim, the pharmaceutical sector's uninterrupted leader for 23 years, continues to provide innovative solutions that facilitate access to treatment for patients experiencing vision loss. The company aims to improve patients' quality of life by introducing Turkey's first biosimilar medicine in ophthalmology.

Abdi İbrahim is strengthening its position in ophthalmology by expanding biotechnology-focused investments with innovative treatment solutions.

Abdi İbrahim Chief Executive Officer Dr. Süha Taşpolatoğlu commented on this significant development as follows: "We have taken an important step in increasing patients' access to high-quality biological products in Turkey. By combining our expertise in ophthalmology with biological products approved in Europe and the United States, we aim to facilitate access to treatment for serious eye diseases such as age-related macular degeneration (AMD). This development reinforces our pioneering role in biotechnology and patient-focused approach, while serving as an important indicator of our commitment to implementing new treatment solutions in critical areas such as ophthalmology and our contribution to the development of the Turkish pharmaceutical sector."

According to September 2025 data, the market for biotechnology products in the ophthalmology field in Turkey is approximately USD 53 million. Strong demand for biotechnology medicines in the country is accelerating adoption of innovative solutions in this field.

Solutions Approved by International Authorities
The treatment provides effective solutions in the treatment of serious eye diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion, and myopic choroidal neovascularization.